European Association of Nuclear Medicine: At an advanced stage prostate cancer frequently leads to bone metastases which may result in pain, fractures, and disability and are associated with a poor prognosis. Recently a major breakthrough has been achieved which is about to improve the patients’ situation, as Prof. Markus Luster, expert of the European Association of Nuclear Medicine (EANM), points out: “Radium-223- dichloride is the first bone-targeted drug that not only alleviates symptoms but also prolongs the life expectancy of these patients.
Latest from John Shanahan
- GEH receives federal funds for BWRX-300 development (World Nuclear News) USofA
- Rejecting carbon colonialism (Paul Driessen, David Wojick, CFACT) USofA
- Move Beyond the Linear No-Threshold Theory for Low-Dose Radiation (J Cardarelli II, B Ulsh) USofA
- Man-made contributions to global warming (Ed Berry) USofA
- Wind Energy in Germany (Edgar Ocampo Tellez) Mexico